Fertility preservation in patients with hormonal receptor positive disease (for example, breast cancer) who would benefit from systemic therapy requires careful consideration, as tamoxifen and aromatase inhibitors have been used in breast cancer patients. The gene discussed is CYP19A1; the disease is glycogen storage disease VI.